We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?
Read MoreHide Full Article
Key Takeaways
ISRG's Q1 revenues rose 19% to $2.25B, with da Vinci procedures up 17% year over year.
ISRG's management raised 2025 procedure growth guidance to 15-17% on global adoption trends.
ISRG's gross margin fell to 66.4% in Q1, pressured by tariffs, depreciation and lower-margin platforms.
Intuitive Surgical (ISRG - Free Report) entered 2025 with strong operational momentum, delivering 17% year-over-year growth in da Vinci procedures and a 19% rise in total revenues (to $2.25 billion) in the first quarter. Notably, day-adjusted procedure growth reached 18.5%, causing management to raise full-year guidance to 15-17%. This growth was supported by robust adoption in general surgery in the United States and accelerated utilization in emerging markets like India, Korea and the United Kingdom. The rollout of the da Vinci 5 platform continued at pace, with 147 new systems placed and over 32,000 procedures completed using the new-generation robot.
However, this clinical and procedural strength faces growing financial headwinds. Gross margins declined to 66.4% in the first quarter from 67.6% a year ago due to increased depreciation, a higher mix of lower-margin platforms like Ion and da Vinci 5, and emerging cost pressures from newly implemented global tariffs. ISRG now expects tariff-driven cost of sales to erode margins by approximately 170 basis points for the full year, revising its gross margin forecast to 65-66.5%.
While recurring revenues remain strong, representing 85% of the total revenues, capital expenditures, manufacturing investments and rising input costs may challenge operating leverage in the near term. Moreover, constrained hospital budgets in key markets like Germany and Japan could tamper the company’s capital placement run rate, adding another layer of margin pressure.
Intuitive Surgical’s solid procedure growth and market adoption are commendable, but they will be tested against a backdrop of tightening margins, macroeconomic headwinds and evolving trade dynamics. Investors should watch closely whether strong volume momentum can continue to outrun inflationary and structural cost drags in the quarters ahead.
Improving Margin for ISRG’s Rivals
In the first quarter of 2025, Stryker (SYK - Free Report) posted strong financials, with organic sales growth of 10.1% and total revenues reaching $5.87 billion, reflecting an 11.9% year-over-year rise. This was driven by robust demand across MedSurg & Neurotechnology and Orthopaedics segments, including standout growth in trauma and extremities, and expanding Mako installations.
Stryker’s adjusted gross margin was 65.5%, up 190 basis points year over year, aided by manufacturing efficiencies, favorable pricing and product mix. Despite a $200 million tariff headwind expected for the year, Stryker maintained operating margin expansion of 100 basis points, reflecting strong cost control and operational leverage.
In contrast, Medtronic (MDT - Free Report) reported 3.9% year-over-year revenue growth in the fourth quarter of fiscal 2025 (to $8.93 billion), with strength in Cardiovascular (up 22% in cardiac ablation), Neuroscience, and Diabetes offsetting surgical headwinds. Medtronic’s gross margin improved to 64.7% (up 19 basis points) and operating margin rose to 26.6%, buoyed by pricing strategies and cost-of-goods-sold productivity gains. However, growth remained uneven across Medtronic’s portfolios.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have gained 0.1% in the year-to-date period against the industry’s decline of 11.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 62.09, above the industry average. But, it is still lower than its five-year median of 72.17. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise from the year-ago period’s level.
Image: Shutterstock
Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?
Key Takeaways
Intuitive Surgical (ISRG - Free Report) entered 2025 with strong operational momentum, delivering 17% year-over-year growth in da Vinci procedures and a 19% rise in total revenues (to $2.25 billion) in the first quarter. Notably, day-adjusted procedure growth reached 18.5%, causing management to raise full-year guidance to 15-17%. This growth was supported by robust adoption in general surgery in the United States and accelerated utilization in emerging markets like India, Korea and the United Kingdom. The rollout of the da Vinci 5 platform continued at pace, with 147 new systems placed and over 32,000 procedures completed using the new-generation robot.
However, this clinical and procedural strength faces growing financial headwinds. Gross margins declined to 66.4% in the first quarter from 67.6% a year ago due to increased depreciation, a higher mix of lower-margin platforms like Ion and da Vinci 5, and emerging cost pressures from newly implemented global tariffs. ISRG now expects tariff-driven cost of sales to erode margins by approximately 170 basis points for the full year, revising its gross margin forecast to 65-66.5%.
While recurring revenues remain strong, representing 85% of the total revenues, capital expenditures, manufacturing investments and rising input costs may challenge operating leverage in the near term. Moreover, constrained hospital budgets in key markets like Germany and Japan could tamper the company’s capital placement run rate, adding another layer of margin pressure.
Intuitive Surgical’s solid procedure growth and market adoption are commendable, but they will be tested against a backdrop of tightening margins, macroeconomic headwinds and evolving trade dynamics. Investors should watch closely whether strong volume momentum can continue to outrun inflationary and structural cost drags in the quarters ahead.
Improving Margin for ISRG’s Rivals
In the first quarter of 2025, Stryker (SYK - Free Report) posted strong financials, with organic sales growth of 10.1% and total revenues reaching $5.87 billion, reflecting an 11.9% year-over-year rise. This was driven by robust demand across MedSurg & Neurotechnology and Orthopaedics segments, including standout growth in trauma and extremities, and expanding Mako installations.
Stryker’s adjusted gross margin was 65.5%, up 190 basis points year over year, aided by manufacturing efficiencies, favorable pricing and product mix. Despite a $200 million tariff headwind expected for the year, Stryker maintained operating margin expansion of 100 basis points, reflecting strong cost control and operational leverage.
In contrast, Medtronic (MDT - Free Report) reported 3.9% year-over-year revenue growth in the fourth quarter of fiscal 2025 (to $8.93 billion), with strength in Cardiovascular (up 22% in cardiac ablation), Neuroscience, and Diabetes offsetting surgical headwinds. Medtronic’s gross margin improved to 64.7% (up 19 basis points) and operating margin rose to 26.6%, buoyed by pricing strategies and cost-of-goods-sold productivity gains. However, growth remained uneven across Medtronic’s portfolios.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have gained 0.1% in the year-to-date period against the industry’s decline of 11.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 62.09, above the industry average. But, it is still lower than its five-year median of 72.17. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2025 earnings implies a 6.8% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.